Inovio Pharmaceuticals

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative

Type
Public
HQ
Blue Bell, US
Size (employees)
157 (est)
Website
inovio.com
Inovio Pharmaceuticals is headquartered in Blue Bell, US

Key People at Inovio Pharmaceuticals

J. Joseph Kim

J. Joseph Kim

CEO

Inovio Pharmaceuticals Office Locations

Inovio Pharmaceuticals has an office in Blue Bell
Blue Bell, US (HQ)
1787 Sentry Parkway West

Inovio Pharmaceuticals Metrics

Inovio Pharmaceuticals Financial Metrics

Revenue (2016)

$8.5 m

Revenue growth (2015-16), %

(79%)

Net income (2016)

($73.7 m)

Market capitalization (21-Mar-2017)

$448.8 m

Closing share price (21-Mar-2017)

$6.1

Cash (31-Dec-2016)

$19.1 m
Inovio Pharmaceuticals's current market capitalization is $448.8 m.
Inovio Pharmaceuticals's revenue was reported to be $8.5 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

$13.5 m$10.5 m$40.6 m$8.5 m

Revenue growth, %

(22%)288%(79%)

Operating expense total

$33 m$50 m$74.9 m$30.9 m

EBIT

($19.5 m)($39.5 m)($34.3 m)($22.4 m)

EBIT margin, %

(145%)(378%)(85%)(263%)

Interest income

$8.6 k$113.2 k$194.5 k$191.5 k

Income tax expense

$308.5 k

Net Income

($66.1 m)($36.1 m)($29.1 m)($73.7 m)
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$33.7 m$40.5 m$57.6 m$19.1 m

Accounts Receivable

$3.3 m$2.8 m$7.3 m$15.8 m

Inventories

$637.4 k$798 k$917.3 k$1.7 m

Current Assets

$58.7 m$98.9 m$171.9 m$124.6 m

Goodwill

$10.1 m$10.1 m$10.1 m$10.5 m

Total Assets

$88.3 m$131.8 m$213.8 m$173.7 m

Accounts Payable

$5.4 m$6.4 m$13.1 m$19.6 m

Current Liabilities

$29 m$14 m$31.5 m$43.8 m

Additional Paid-in Capital

$348.1 m$443.3 m$534 m$556.7 m

Retained Earnings

($295.8 m)($331.9 m)($361.1 m)($434.8 m)

Total Equity

$52.9 m$111.5 m$175.9 m$123.4 m

Financial Leverage

1.7 x1.2 x1.2 x1.4 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($66.1 m)($36.1 m)($29.1 m)($73.7 m)

Depreciation and Amortization

$2.1 m$1.6 m$1.9 m$3.1 m

Accounts Receivable

($2.5 m)$499.2 k($4.5 m)($8.5 m)

Inventories

($229.7 k)($160.5 k)($119.3 k)($831.8 k)

Accounts Payable

$2.2 m$1.5 m$6.5 m$6.4 m

Cash From Operating Activities

($15.4 m)($29.8 m)($12.4 m)($62.6 m)

Cash From Investing Activities

($9.2 m)($35.8 m)($54.8 m)$16.3 m

Inovio Pharmaceuticals Market Value History

Inovio Pharmaceuticals Online Presence

Inovio Pharmaceuticals News

Inovio Pharmaceuticals Company Life

You may also be interested in